FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1843791750> ?p ?o ?g. }

• W1843791750 endingPage "267" @default.
• W1843791750 startingPage "261" @default.
• W1843791750 abstract "We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin, and methotrexate (FAMTX) in previously untreated patients with advanced esophagogastric cancer.Two hundred seventy-four patients with adenocarcinoma or undifferentiated carcinoma were randomized and analyzed for survival, tumor response, toxicity, and quality of life (QL).The overall response rate was 45% (95% confidence interval [CI], 36% to 54%) with ECF and 21% (95% CI, 13% to 29%) with FAMTX (P = .0002). Toxicity was tolerable and there were only three toxic deaths. The FAMTX regimen caused more hematologic toxicity and serious infections, but ECF caused more emesis and alopecia. The median survival duration was 8.9 months with ECF and 5.7 months with FAMTX (P = .0009); at 1 year, 36% (95% CI, 27% to 45%) of ECF and 21% (95% CI, 14% to 29%) of FAMTX patients were alive. The median failure-free survival duration was 7.4 months with ECF and 3.4 months with FAMTX (P = .00006). The global QL scores were better for ECF at 24 weeks, but the remaining QL data showed no differences between either arm of the study. Hospital-based cost analysis on a subset of patients was similar for each arm and translated into an increment cost of $975 per life-year gained.The ECF regimen results in a survival and response advantage, tolerable toxicity, better QL and cost-effectiveness compared with FAMTX chemotherapy. This regimen should now be considered the standard treatment for advanced esophagogastric cancer." @default.
• W1843791750 created "2016-06-24" @default.
• W1843791750 creator A5001503641 @default.
• W1843791750 creator A5002600575 @default.
• W1843791750 creator A5011528245 @default.
• W1843791750 creator A5015019664 @default.
• W1843791750 creator A5016115321 @default.
• W1843791750 creator A5017029994 @default.
• W1843791750 creator A5024785329 @default.
• W1843791750 creator A5027160662 @default.
• W1843791750 creator A5040757638 @default.
• W1843791750 creator A5052183696 @default.
• W1843791750 creator A5052620856 @default.
• W1843791750 creator A5054875746 @default.
• W1843791750 creator A5056345420 @default.
• W1843791750 creator A5061348179 @default.
• W1843791750 creator A5065178599 @default.
• W1843791750 creator A5066606548 @default.
• W1843791750 creator A5066736483 @default.
• W1843791750 creator A5080984611 @default.
• W1843791750 creator A5082292420 @default.
• W1843791750 date "1997-01-01" @default.
• W1843791750 modified "2023-10-16" @default.
• W1843791750 title "Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer." @default.
• W1843791750 cites W1863898801 @default.
• W1843791750 cites W1883602322 @default.
• W1843791750 cites W1902766545 @default.
• W1843791750 cites W1940613095 @default.
• W1843791750 cites W1976651872 @default.
• W1843791750 cites W2023398895 @default.
• W1843791750 cites W2031182553 @default.
• W1843791750 cites W2034294525 @default.
• W1843791750 cites W2036409540 @default.
• W1843791750 cites W2036745924 @default.
• W1843791750 cites W2044889252 @default.
• W1843791750 cites W2069183803 @default.
• W1843791750 cites W2103770024 @default.
• W1843791750 cites W2110617366 @default.
• W1843791750 cites W2111923167 @default.
• W1843791750 cites W2167571044 @default.
• W1843791750 cites W2409031629 @default.
• W1843791750 cites W2414529548 @default.
• W1843791750 doi "https://doi.org/10.1200/jco.1997.15.1.261" @default.
• W1843791750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8996151" @default.
• W1843791750 hasPublicationYear "1997" @default.
• W1843791750 type Work @default.
• W1843791750 sameAs 1843791750 @default.
• W1843791750 citedByCount "576" @default.
• W1843791750 countsByYear W18437917502012 @default.
• W1843791750 countsByYear W18437917502013 @default.
• W1843791750 countsByYear W18437917502014 @default.
• W1843791750 countsByYear W18437917502015 @default.
• W1843791750 countsByYear W18437917502016 @default.
• W1843791750 countsByYear W18437917502017 @default.
• W1843791750 countsByYear W18437917502018 @default.
• W1843791750 countsByYear W18437917502019 @default.
• W1843791750 countsByYear W18437917502020 @default.
• W1843791750 countsByYear W18437917502021 @default.
• W1843791750 countsByYear W18437917502022 @default.
• W1843791750 countsByYear W18437917502023 @default.
• W1843791750 crossrefType "journal-article" @default.
• W1843791750 hasAuthorship W1843791750A5001503641 @default.
• W1843791750 hasAuthorship W1843791750A5002600575 @default.
• W1843791750 hasAuthorship W1843791750A5011528245 @default.
• W1843791750 hasAuthorship W1843791750A5015019664 @default.
• W1843791750 hasAuthorship W1843791750A5016115321 @default.
• W1843791750 hasAuthorship W1843791750A5017029994 @default.
• W1843791750 hasAuthorship W1843791750A5024785329 @default.
• W1843791750 hasAuthorship W1843791750A5027160662 @default.
• W1843791750 hasAuthorship W1843791750A5040757638 @default.
• W1843791750 hasAuthorship W1843791750A5052183696 @default.
• W1843791750 hasAuthorship W1843791750A5052620856 @default.
• W1843791750 hasAuthorship W1843791750A5054875746 @default.
• W1843791750 hasAuthorship W1843791750A5056345420 @default.
• W1843791750 hasAuthorship W1843791750A5061348179 @default.
• W1843791750 hasAuthorship W1843791750A5065178599 @default.
• W1843791750 hasAuthorship W1843791750A5066606548 @default.
• W1843791750 hasAuthorship W1843791750A5066736483 @default.
• W1843791750 hasAuthorship W1843791750A5080984611 @default.
• W1843791750 hasAuthorship W1843791750A5082292420 @default.
• W1843791750 hasConcept C126322002 @default.
• W1843791750 hasConcept C141071460 @default.
• W1843791750 hasConcept C2776694085 @default.
• W1843791750 hasConcept C2776755627 @default.
• W1843791750 hasConcept C2778397455 @default.
• W1843791750 hasConcept C2778496288 @default.
• W1843791750 hasConcept C2780456651 @default.
• W1843791750 hasConcept C2780835546 @default.
• W1843791750 hasConcept C2781413609 @default.
• W1843791750 hasConcept C29730261 @default.
• W1843791750 hasConcept C71924100 @default.
• W1843791750 hasConcept C90924648 @default.
• W1843791750 hasConceptScore W1843791750C126322002 @default.
• W1843791750 hasConceptScore W1843791750C141071460 @default.
• W1843791750 hasConceptScore W1843791750C2776694085 @default.
• W1843791750 hasConceptScore W1843791750C2776755627 @default.
• W1843791750 hasConceptScore W1843791750C2778397455 @default.
• W1843791750 hasConceptScore W1843791750C2778496288 @default.

• next